Showing 1–25 of 34 · Medical devices & monitoring
FY2025 revenue $44.33bn (+5.7%); operating margin 18.2%; net income $6.52bn.
Balance sheet figures not captured from release.
FY2026 revenue $401.9m (-12.3%); operating margin -6.6%; net loss $49.2m.
Cash $41.2m; debt $147.9m.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue $11.24bn (+5.7%); operating margin -2.7%; net loss $957.0m.
Continuing operations; operating loss after impairment and restructuring charges.
FY2026 revenue $19.46bn (+4.9%); operating margin 11.6%; net income $1.15bn.
Continuing operations; net income from continuing operations $1.42bn (+29%).
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue $20.07bn (+19.9%); operating margin 18.0%; net income $2.90bn.
Balance sheet figures not captured from release.
FY2026 revenue $254.25bn (+14.0%); operating margin 1.0%; net income $1.71bn.
Cash $4.86bn; debt $8.89bn.
FY2025 revenue $4.66bn (+15.6%); operating margin 19.6%; net income $836.3m.
Cash $2.00bn; debt $1.24bn.
FY2025 revenue €3.48bn (+3.3%); operating margin 6.7%; net income €140.4m.
Balance sheet figures not captured from release.
FY2025 revenue $6.07bn (+11.5%); operating margin 20.8%; net income $1.06bn.
Cash $3.00bn; debt $600.0m.
FY2025/26 revenue SEK 16.72bn (-7.2%); operating margin 1.4%; net loss SEK 517.0m.
EBIT hit by impairments and restructuring; adjusted EBIT SEK 2.05bn; net debt SEK 3.19bn.
FY2025 revenue €19.63bn (+1.5%); operating margin 9.3%; net income €978.0m.
Net debt €9.20bn.
FY2025 revenue $20.62bn (+4.8%); operating margin 13.4%; net income $2.08bn.
Cash $4.51bn; debt $10.00bn.
FY2025 adjusted EBITA SEK 4.88bn, a 14.0% adjusted margin; organic growth 4.9%.
Band uses the adjusted margin; reported net sales and profit not yet captured.
FY2025 revenue $2.23bn (-6.3%); operating margin 1.9%; net income $0.7m.
Cash $308.0m; debt $1.28bn.
FY2025 revenue $2.71bn (+30.7%); operating margin 17.5%; net income $247.1m.
Cash $716.1m; debt $949.2m.
Parent Johnson & Johnson (JNJ) group FY2025 revenue $94.19bn (+6.0%); pre-tax margin 34.6%; net income $26.80bn.
MedTech segment sales $33.79bn (+6.1%).
FY2025 revenue $1.53bn (+9.4%).
Preliminary revenue only; full GAAP results not yet captured.
FY2026 revenue $36.36bn (+8.4%); operating margin 17.8%; net income $4.80bn.
Balance sheet figures not captured from release.
FY2025 revenue RMB 33.28bn (-9.4%); net margin 25.4%; net income RMB 8.45bn.
Net profit fell 30.3%; operating profit not stated in summary.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Listed (6849.T).
Latest full-year results not yet captured by HSH.
FY2025 revenue ¥1.01tn (+1.3%); operating margin 9.6%; net income ¥68.2bn.
Balance sheet figures not captured from release.
FY2025 revenue €17.83bn (-1.0%); operating margin 8.0%; net income €895.0m.
Net debt €5.29bn.